touchNEUROLOGY met with Michael Marmura (Thomas Jefferson University, Jefferson Headache Center, Philadelphia, PA, USA) to discuss his study investigating intranasal ketamine for the treatment of refractory headache.
The abstract ‘Intranasal Ketamine for Refractory Headache’ was presented at the American Headache Society (AHS) Virtual Annual Scientific Meeting 2021, 3-6 June 2021.
Questions:
- What is the rationale for using intranasal ketamine in the acute treatment of refractory headache? (0:21)
- Could you tell us a little about your retrospective study and its patient population? (1:10)
- What were the study efficacy and safety findings? (2:57)
- What is the ideal dosing of intranasal ketamine in adults? (4:40)
- Who is likely to benefit most from intranasal ketamine and in whom is it contraindicated? (6:02)
Disclosures: Within the past 24 months, Michael Marmura has received compensation for consultation from Alder/Lumbeck, Lilly, Supernus, and Theranica; has participated in speaker bureaus for Eli Lilly, and Amgen/Novartis; has received institutional support for serving as principal investigator from Teva, GammaCore and Allergan/AbbVie; and has received payments for authorship or royalties from Demos Medical, Cambridge University Press and MedLink.
Support: Interview and filming supported by Touch Medical Media. Interview conducted by Katey Gabrysch.
Filmed as a highlight of AHS Virtual Annual Scientific Meeting 2021
